Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction

Transfusion

Volumn 54, Issue 5, 2014, Pages 1321-1331

  Coene, José ^a   Devreese, Katrien ^b   Sabot, Bea ^a   Feys, Hendrik B ^c   Vandekerckhove, Philippe ^a   Compernolle, Veerle ^a  

^a Red Cross Flanders   (Belgium)

^b Transfusion Research Center   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; FIBRINOGEN; METHYLENE BLUE; PLASMA PROTEIN; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; RIBOFLAVIN;

ANALYSIS OF VARIANCE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; HEMATOLOGY ANALYZER; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATHOGEN CLEARANCE; PATHOGEN REDUCTION METHOD; PATHOGEN REDUCTION SYSTEM; PLASMA; PROTHROMBIN TIME; SAMPLING; THROMBIN TIME;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PROTEINS; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; FEMALE; HUMANS; MALE; PARTIAL THROMBOPLASTIN TIME; THROMBIN;

EID: 84900483776     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12460     Document Type: Article

References (34)

1. Alter HJ,. Pathogen reduction: A precautionary principle paradigm. Transfus Med Rev 2008; 22: 97-102. (Pubitemid 351381952)
2. Lambrecht B, Mohr H, Knuver-Hopf J, et al. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991; 60: 207-213.
3. Singh Y, Sawyer LS, Pinkoski LS, et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006; 46: 1168-1177. (Pubitemid 44139491)
4. Goodrich RP, Edrich RA, Li J, et al. The Mirasol PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17. (Pubitemid 44354317)
5. Cid J, Ramiro L, Martinez N, et al. Quantitative and qualitative analysis of proteins in fresh frozen plasma obtained from whole blood donations and prepared with two photochemical treatments. Transfus Apher Sci 2008; 39: 115-121.
6. Osselaer JC, Debry C, Goffaux M, et al. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 2008; 48: 108-117.
7. Seghatchian J, Struff WG, Reichenberg S,. Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transfus Med Hemother 2011; 38: 55-64.
8. Bihm DJ, Ettinger A, Buytaert-Hoefen KA, et al. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C. Vox Sang 2010; 98: 108-115.
9. Irsch J, Pinkoski L, Corash L, et al. INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function-An in vitro analysis. Vox Sang 2010; 98: 47-55.
10. Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline-third edition. CLSI document C28-A3. Wayne, (PA): Clinical and Laboratory Standards Institute, 2008.
11. Devreese K, Wijns W, Combes I, et al. Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis. Thromb Haemost 2007; 98: 600-613. (Pubitemid 47412886)
12. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15. (Pubitemid 37449290)
13. Benjamin RJ, McLaughlin LS,. Plasma components: properties, differences, and uses. Transfusion 2012; 52: 9S-19S.
14. Williamson LM, Cardigan R, Prowse CV,. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003; 43: 1322-1329. (Pubitemid 37082695)
15. Thiele T, Kellner S, Hron G, et al. Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivation. Transfusion 2012; 52: 529-536.
16. Zeiler T, Wittmann G, Zimmermann R, et al. The effect of virus inactivation on coagulation factors in therapeutic plasma. Br J Haematol 2000; 111: 986-987. (Pubitemid 32098942)
17. Smith J, Rock G,. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2010; 50: 926-931.
18. Prowse C,. Properties of pathogen-inactivated plasma components. Transfus Med Rev 2009; 23: 124-133.
19. Rock G,. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011; 100: 169-178.
20. Atance R, Pereira A, Ramirez B,. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001; 41: 1548-1552. (Pubitemid 34072680)
21. Solheim BG, Cid J, Osselaer JC,. Pathogen reduction technologies. In:, Lozano M, Contreras M, Blajchman M, editors. Global perspectives in transfusion medicine. Bethesda (MD): American Association of Blood Banks Press; 2006. p. 103-148.
22. Politis C, Kavallierou L, Hantziara S, et al. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang 2007; 92: 319-326. (Pubitemid 46642985)
23. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45: 1362-1372. (Pubitemid 41647805)
24. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002; 42: 1302-1307.
25. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107: 3753-3760.
26. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 16th ed. Strasbourg: Directorate for the Quality of Medicines & Health Care of the Council of Europe; 2011.
27. Solheim BG, Hellstern P,. Pathogen inactivation of plasma and cryoprecipitate. In:, Aubuchon JP, Prowse CV, editors. Pathogen inactivation-the penultimate paradigm shift. Bethesda (MD): American Association of Blood Banks Press; 2010. p. 69-98.
28. Butenas S, van't Veer C, Mann KG,. "Normal" thrombin generation. Blood 1999; 94: 2169-2178.
29. Cardigan R, Philpot K, Cookson P, et al. Thrombin generation and clot formation in methylene blue-treated plasma and cryoprecipitate. Transfusion 2009; 49: 696-703.
30. Pock K, Heger A, Janisch S, et al. Thrombin generation capacity is impaired in methylene-blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a licensed solvent/detergent-treated plasma (Octaplas) and a development product (Uniplas). Transfus Apher Sci 2007; 37: 223-231. (Pubitemid 350181792)
31. Gravemann U, Kusch M, Koenig H, et al. Thrombin generation capacity of methylene blue-treated plasma prepared by the Theraflex MB plasma system. Transfus Med Hemother 2009; 36: 122-127.
32. Hacquard M, Lecompte T, Belcour B, et al. Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas. Vox Sang 2012; 102: 354-361.
33. Lawrie AS, Cardigan RA, Williamson LM, et al. The dynamics of clot formation in fresh-frozen plasma. Vox Sang 2008; 94: 306-314. (Pubitemid 351535735)
34. Filippin LD, Noubouossié D, Lê PQ, et al. Test de génération de thrombine: importance d'établir des valeurs de référence en fonction de l'âge et des concentrations en facteur tissulaire avant l'implémentation au laboratoire. Rev Med Brux 2011; 32: 69-73.